We are live on ! Find out more
KAM

Kazazian Asset Management Portfolio holdings

AUM $111M
1-Year Est. Return 29.02%
This Fund
S&P 500
This Quarter Est. Return
+4.5%
1 Year Est. Return
+29.02%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$109M
AUM Growth
+$13.7M
Cap. Flow
+$11.8M
Cap. Flow %
10.79%
Top 10 Hldgs %
52.61%
Holding
94
New
9
Increased
24
Reduced
52
Closed
6

Sector Composition

Rank Sector Weight
1 Healthcare 31.91%
2 Miscellaneous 25.64%
3 Financials 12.01%
4 Consumer Discretionary 9.86%
5 Communication Services 6.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GDX icon
51
VanEck Gold Miners ETF
GDX
$28.3B
$424K 0.39%
19,025
-20,835
-52% -$467K
ICPT
52
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$421K 0.39%
5,012
-192
-4% -$14.1K
NKTR icon
53
Nektar Therapeutics
NKTR
$2.34B
$420K 0.39%
573
-544
-49% -$627K
ACOR
54
DELISTED
Acorda Therapeutics
ACOR
$415K 0.38%
+120
New +$367K
CXO
55
DELISTED
CONCHO RESOURCES INC.
CXO
$408K 0.37%
2,949
-162
-5% -$23.2K
PXD
56
DELISTED
Pioneer Natural Resource Co.
PXD
$406K 0.37%
2,144
-118
-5% -$22.6K
PE
57
DELISTED
PARSLEY ENERGY INC
PE
$360K 0.33%
11,881
-654
-5% -$19.3K
APA icon
58
APA Corp
APA
$15.8B
$355K 0.33%
7,593
-418
-5% -$17.3K
KPTI icon
59
Karyopharm Therapeutics
KPTI
$36.3M
$351K 0.32%
+1,378
New +$341K
CORI
60
DELISTED
Corium International, Inc.
CORI
$351K 0.32%
43,854
+24,336
+125% +$230K
AAMC
61
DELISTED
Altisource Asset Management Corp
AAMC
$350K 0.32%
8,529
-527
-6% -$20.3K
SRRA
62
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$350K 0.32%
2,957
-138
-4% -$13.8K
ECYT
63
DELISTED
Endocyte, Inc. Common Stock
ECYT
$346K 0.32%
25,058
-7,465
-23% -$88.6K
NTLA icon
64
Intellia Therapeutics
NTLA
$1.66B
$343K 0.31%
12,530
+2,773
+28% +$67.2K
GM.WS.B
65
DELISTED
General Motors Company
GM.WS.B
$342K 0.31%
15,161
-1,653
-10% -$35.9K
CTRA
66
DELISTED
Coterra Energy
CTRA
$338K 0.31%
14,205
-781
-5% -$18.2K
PTEN icon
67
Patterson-UTI
PTEN
$4.74B
$322K 0.3%
17,867
-983
-5% -$19.7K
ARRY
68
DELISTED
Array Biopharma Inc
ARRY
$314K 0.29%
18,713
-716
-4% -$11.4K
NBIS
69
Nebius Group N.V.
NBIS
$57.7B
$302K 0.28%
8,413
+1,720
+26% +$59.9K
BTU icon
70
Peabody Energy
BTU
$3.33B
$300K 0.28%
6,594
-366
-5% -$15K
BMRN icon
71
BioMarin Pharmaceuticals
BMRN
$12.9B
$295K 0.27%
3,134
-120
-4% -$10.5K
GDXJ icon
72
VanEck Junior Gold Miners ETF
GDXJ
$8.96B
$291K 0.27%
8,903
UTHR icon
73
United Therapeutics
UTHR
$21.3B
$284K 0.26%
+2,506
New +$275K
WFT
74
DELISTED
Weatherford International plc
WFT
$265K 0.24%
80,401
-4,424
-5% -$13.8K
INTC icon
75
Intel
INTC
$514B
$257K 0.24%
5,160
-20,248
-80% -$1.08M

Similar funds

Kazazian Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Kazazian Asset Management held 94 positions worth $109M, up 14% from $95.4M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Kazazian Asset Management deployed $11.8M of net new capital in Q2 2018, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Walt Disney: 12,000 shares worth $1.26M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 30% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.11M trimmed.

  • Kazazian Asset Management's largest Q2 2018 buy was Walt Disney: 12,000 shares worth $1.26M.
  • Kazazian Asset Management added most to iShares MSCI Emerging Markets ETF in Q2 2018, an estimated $2.81M increase.
  • Kazazian Asset Management's biggest Q2 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.11M.
  • Kazazian Asset Management fully exited State Street SPDR S&P Oil & Gas Exploration & Production ETF in Q2 2018, selling an estimated $2.11M.
  • Kazazian Asset Management's ten largest holdings make up 53% of its $109M portfolio in Q2 2018.
  • Kazazian Asset Management opened 9 new positions and closed 6 in Q2 2018.
  • Kazazian Asset Management's portfolio value rose 14% quarter-over-quarter to $109M.

Based on Kazazian Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.